A Phase 3 interventional study of E/C/F/TAF and F/R/TAF in HIV-1 Infection and HCV Infection, sponsored by Gilead Sciences. Completed at 43 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-14.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Hepatitis C by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Hepatitis C · Gilead Sciences.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 39th largest by enrollment of the 97 interventional ones that give a count, is one of 13 that started in 2016, is one of 35 in phase 3, and was the 91st registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 110 studies in Hepatitis C by Gilead Sciences is open now. The open studies under Hepatitis C, anywhere →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 49 · Phase 3 35 · Phase 4 1
First in 2006; this study’s year is marked. 13 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 111 across the 97 interventional studies, 785 across the 12 observational. Of the 109 that completed or were terminated, 79 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 110 studies in Hepatitis C by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or emtricitabine/rilpivirine/tenofovir alafenamide (F/R/TAF) from the current antiretroviral (ARV) therapy and in virologically-suppressed, HIV-1/HCV co-infected participants.
Key Inclusion Criteria:
For individuals with 3 or more prior ARV regimens, a regimen history should be provided for approval by the Sponsor.
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1: Participants will switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) plus a third agent to E/C/F/TAF. Part 2: After 8 weeks of E/C/F/TAF treatment, the participants maintaining HIV-1 RNA \< 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study.
Drug: E/C/F/TAF · Drug: LDV/SOF
Part 1: Participants will switch from 2 NRTI plus a third agent to F/R/TAF. Part 2: After 8 weeks of F/R/TAF treatment, the participants maintaining HIV-1 RNA \< 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study.
Drug: F/R/TAF · Drug: LDV/SOF
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
Also known as: Genvoya®
Drug page: Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate
200/25/25 mg FDC tablet administered orally once daily
Also known as: Odefsey®
90/400 mg FDC tablet administered orally once daily
Also known as: Harvoni®, GS-5885/GS-7977
Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)
Sustained Virologic Response (SVR12) was defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment.
Time frame: HCV Posttreatment Week 12
Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4)
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping LDV/SOF treatment.
Time frame: HCV Posttreatment Week 4
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: 24 weeks after start of HIV treatment
Percentage of Participants Experiencing Grades 1 Through 4 Adverse Events After Switch to E/C/F/TAF or F/R/TAF Throughout the Study and During Coadministeration With LDV/SOF Treatment
Time frame: Up to 32 weeks plus 30 days
Participants were enrolled at study sites in the United States. The first participant was screened on 01 April 2016. The last study visit occurred on 29 September 2017.
| Milestone | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF |
|---|---|---|
| Started | 76 | 74 |
| Completed | 72 | 70 |
| Not completed | 4 | 4 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Investigator's discretion | 1 | 0 |
| Withdrew: Withdrew consent | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Participants randomized but not treated | 2 | 0 |
Sustained Virologic Response (SVR12) was defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment.
| percentage of participants | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF |
|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12) | 98.6 (92.5 to 100.0) | 95.8 (88.3 to 99.1) |
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping LDV/SOF treatment.
| percentage of participants | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF |
|---|---|---|
| Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4) | 98.6 (92.5 to 100.0) | 98.6 (92.5 to 100.0) |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm | 1.4 | 1.4 |
| percentage of participants | E/C/F/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | F/R/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | E/C/F/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV Week 12) | F/R/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV to Week 12) |
|---|---|---|---|---|
| Percentage of Participants Experiencing Grades 1 Through 4 Adverse Events After Switch to E/C/F/TAF or F/R/TAF Throughout the Study and During Coadministeration With LDV/SOF Treatment | 62.5 | 69.4 | 83.8 | 79.7 |
Collected over Up to 32 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E/C/F/TAF + LDV/SOF | 0/74 (0%) | 7/74 (9.5%) | 46/74 (62.2%) |
| F/R/TAF + LDV/SOF | 1/74 (1.4%) | 12/74 (16.2%) | 36/74 (48.6%) |
| Event | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF |
|---|---|---|
| PneumoniaInfections and infestations | 0/74 | 2/74 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/74 | 0/74 |
| Abdominal painGastrointestinal disorders | 0/74 | 1/74 |
| AstheniaGeneral disorders | 0/74 | 1/74 |
| Chest painGeneral disorders | 0/74 | 1/74 |
| GastroenteritisInfections and infestations | 1/74 | 0/74 |
| InfluenzaInfections and infestations | 0/74 | 1/74 |
| Testicular abscessInfections and infestations | 0/74 | 1/74 |
| Tooth infectionInfections and infestations | 1/74 | 0/74 |
| Ankle fractureInjury, poisoning and procedural complications | 0/74 | 1/74 |
| Event | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF |
|---|---|---|
| Urinary tract infectionInfections and infestations | 10/74 | 2/74 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/74 | 10/74 |
| Upper respiratory tract infectionInfections and infestations | 9/74 | 5/74 |
| HeadacheNervous system disorders | 3/74 | 8/74 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/74 | 5/74 |
| DiarrhoeaGastrointestinal disorders | 6/74 | 3/74 |
| NauseaGastrointestinal disorders | 4/74 | 6/74 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/74 | 1/74 |
| FatigueGeneral disorders | 4/74 | 5/74 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 5/74 | 2/74 |
Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug (E/C/F/TAF, F/R/TAF, or LDV/SOF).
| Age, Continuous(years) | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF | Total |
|---|---|---|---|
| Mean | 51 ± 9.5 | 52 ± 9.9 | 51 ± 9.7 |
| Sex: Female, Male(Participants) | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF | Total |
|---|---|---|---|
| Female | 16 | 22 | 38 |
| Male | 58 | 52 | 110 |
| Ethnicity (NIH/OMB)(Participants) | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 14 | 27 |
| Not Hispanic or Latino | 61 | 59 | 120 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF | Total |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| Black | 30 | 31 | 61 |
| White | 41 | 37 | 78 |
| Native Hawaiian or Pacific Islander | 0 | 2 | 2 |
| Other | 2 | 3 | 5 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| HCV RNA Category(Participants) | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF | Total |
|---|---|---|---|
| < 800,000 IU/mL | 25 | 14 | 39 |
| ≥ 800,000 IU/mL | 49 | 60 | 109 |
| HIV-1 RNA Category(Participants) | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF | Total |
|---|---|---|---|
| < 50 copies/mL | 73 | 74 | 147 |
| ≥ 50 copies/mL | 1 | 0 | 1 |
| HCV RNA(log10 IU/mL) | E/C/F/TAF + LDV/SOF | F/R/TAF + LDV/SOF | Total |
|---|---|---|---|
| Mean | 6.0 ± 1.07 | 6.3 ± 0.74 | 6.2 ± 0.92 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Apr 2016 to primary completion in Sep 2017, 17 months.
Results were first posted in Oct 2018, 1 year after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 17 months is above that.
Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate